Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 611-624

  Li, Guangliang ^a   Zhang, Jing ^a   Jin, Ketao ^a,c   He, Kuifeng ^a   Zheng, Yi ^a   Xu, Xin ^a   Wang, Haohao ^a   Wang, Haiyong ^a   Li, Zhongqi ^a   Yu, Xiongfei ^a   Teng, Xiaodong ^a   Cao, Jiang ^b   Teng, Lisong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Acquired tamoxifen resistance; Breast cancer; ER 36; ER 66 and EGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 36; ESTROGEN RECEPTOR ALPHA 66; MESSENGER RNA; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; DOWN REGULATION; DRUG SENSITIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STABLE TRANSFECTION; WESTERN BLOTTING;

EID: 84878115770     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.001     Document Type: Article

References (56)

1. Aguilar H., Sole X., Bonifaci N., Serra-Musach J., Islam A., Lopez-Bigas N., Mendez-Pertuz M., Beijersbergen R.L., Lazaro C., Urruticoechea A., Pujana M.A. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. Oncogene 2010, 29:6071-6083.
2. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. Journal of Biological Chemistry 1995, 270:27489-27494.
3. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews Cancer 2002, 2:101-112.
4. Arpino G. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest oncology group study. Clinical Cancer Research 2004, 10:5670-5676.
5. Arpino G., Wiechmann L., Osborne C.K., Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 2008, 29:217-233.
6. Bayliss J., Hilger A., Vishnu P., Diehl K., El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical Cancer Research 2007, 13:7029-7036.
7. Chaudhri R.A., Olivares-Navarrete R., Cuenca N., Hadadi A., Boyan B.D., Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). The Journal of Biological Chemistry 2012, 287:7169-7181.
8. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
9. Creighton C.J., Hilger A.M., Murthy S., Rae J.M., Chinnaiyan A.M., El-Ashry D. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Research 2006, 66:3903-3911.
10. deFazio A., Chiew Y.E., McEvoy M., Watts C., Sutherland R.L. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research 1997, 8:903.
11. Dudley D.T., Pang L., Decker S.J., Bridges A.J., Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proceedings of the National Academy of Sciences 1995, 92:7686-7689.
12. Fan P., Wang J., Santen R.J., Yue W. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Research 2007, 67:1352-1360.
13. Filardo E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 2002, 80:231-238.
14. Fox E.M., Bernaciak T.M., Wen J., Weaver A.M., Shupnik M.A., Silva C.M. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Molecular Endocrinology 2008, 22:1781-1796.
15. Gutierrez M.C., Detre S., Johnston S., Mohsin S.K., Shou J., Allred D.C., Schiff R., Osborne C.K., Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of Clinical Oncology 2005, 23:2469-2476.
16. Hiscox S., Morgan L., Barrow D., Dutkowski C., Wakeling A., Nicholson R.I. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib (Iressa', ZD1839). Clinical and Experimental Metastasis 2004, 21:201-212.
17. Hiscox S., Jiang W.G., Obermeier K., Taylor K., Morgan L., Burmi R., Barrow D., Nicholson R.I. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. International Journal of Cancer 2006, 118:290-301.
18. Holloway J.N., Murthy S., El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Molecular Endocrinology 2004, 18:1396-1410.
19. Ignatov A., Ignatov T., Roessner A., Costa S.D., Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Research and Treatment 2010, 123:87-96.
20. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer: twenty-eight years later. Journal of Clinical Oncology 1995, 13:513-529.
21. Johnston S., Saccani-Jotti G., Smith I., Salter J., Newby J., Coppen M., Ebbs S., Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Research 1995, 55:3331-3338.
22. Jorissen R. Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research 2003, 284:31-53.
23. Kang L., Zhang X., Xie Y., Tu Y., Wang D., Liu Z., Wang Z.Y. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Molecular Endocrinology 2010, 24:709-721.
24. Kang L., Guo Y., Zhang X., Meng J., Wang Z.Y. A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 2011, 127:262-268.
25. Knowlden J.M., Hutcheson I.R., Jones H.E., Madden T., Gee J.M.W., Harper M.E., Barrow D., Wakeling A.E., Nicholson R.I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-1044.
26. Lee C.S.L., Hall R.E., Alexander I.E., Koga M., Shine J., Sutherland R.L. Inverse relationship between estrogen receptor and epidermal growth factor receptor mRNA levels in human breast cancer cell lines. Growth Factors 1990, 3:97-103.
27. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995, 267:1782.
28. Lin S.L., Yan L.Y., Liang X.W., Wang Z.B., Wang Z.Y., Qiao J., Schatten H., Sun Q.Y. A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reproductive Biology and Endocrinology: RB&E 2009, 7:102.
29. Lin S.L., Yan L.Y., Zhang X.T., Yuan J., Li M., Qiao J., Wang Z.Y., Sun Q.Y. ER-α36, a variant of ER-α, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PloS One 2010, 5:e9013.
30. -ΔΔCT method. Methods 2001, 25:402-408.
31. Massarweh S., Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine Related Cancer 2006, 13(Suppl. 1):S15-S24.
32. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., Weiss H., Rimawi M., Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 2008, 68:826-833.
33. Oesterreich S., Zhang P., Guler R.L., Sun X., Curran E.M., Welshons W.V., Osborne C.K., Lee A.V. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Research 2001, 61:5771-5777.
34. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Molecular Endocrinology 2001, 15:1344-1359.
35. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine 2011, 62:233-247.
36. Pancholi S., Lykkesfeldt A.E., Hilmi C., Banerjee S., Leary A., Drury S., Johnston S., Dowsett M., Martin L.A. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocrine Related Cancer 2008, 15:985-1002.
37. Ruder H.J., Loriaux L., Lipsett M. Estrone sulfate: production rate and metabolism in man. Journal of Clinical Investigation 1972, 51:1020.
38. Santen R.J., Fan P., Zhang Z., Bao Y., Song R.X.D., Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 2009, 74:586-594.
39. Shi L., Dong B., Li Z., Lu Y., Ouyang T., Li J., Wang T., Fan Z., Fan T., Lin B., Wang Z., Xie Y. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. Journal of Clinical Oncology 2009, 27:3423-3429.
40. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer Journal of Clinicians 2011, 61:212-236.
41. Stoica A., Saceda M., Doraiswamy V., Coleman C., Martin M. Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. Journal of Endocrinology 2000, 165:371-378.
42. Stossi F., Madak-Erdogan Z., Katzenellenbogen B.S. Macrophage-elicited loss of estrogen receptor-alpha in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus. Oncogene 2012, 31:1825-1834.
43. Tong J.S., Zhang Q.H., Wang Z.B., Li S., Yang C.R., Fu X.Q., Hou Y., Wang Z.Y., Sheng J., Sun Q.Y. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway. PloS One 2010, 5:e15408.
44. Tu B.B., Lin S.L., Yan L.Y., Wang Z.Y., Sun Q.Y., Qiao J. ER-alpha36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. American Journal of Obstetrics and Gynecology 2011, 205(227):e221-226.
45. Van den Berg H., Lynch M., Martin J., Nelson J., Dickson G., Crockard A. Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. British Journal of Cancer 1989, 59:522.
46. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochemical and Biophysical Research Communications 2005, 336:1023-1027.
47. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proceedings of the National Academy of Sciences USA 2006, 103:9063-9068.
48. Yarden R.I., Lauber A., El-Ashry D., Chrysogelos S. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 1996, 137:2739-2747.
49. Yarden R.I., Wilson M.A., Chrysogelos S.A. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. Journal of Cellular Biochemistry 2001, 81:232-246.
50. Zhang Y., Su H., Rahimi M., Tochihara R., Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. International Journal of Cancer 2009, 125:2021-2028.
51. Zhang X.T., Kang L.G., Ding L., Vranic S., Gatalica Z., Wang Z.Y. A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011, 30:770-780.
52. Zhang J., Li G., Li Z., Yu X., Zheng Y., Jin K., Wang H., Gong Y., Sun X., Teng X., Cao J., Teng L. Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids 2012, 77:666-673.
53. Zhang X., Ding L., Kang L., Wang Z.Y. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One 2012, 7:e30174.
54. Zhao Y., Deng C., Lu W., Xiao J., Ma D., Guo M., Recker R.R., Gatalica Z., Wang Z., Guishan Xiao G. let-7MicroRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Molecular Medicine 2011, 17:1233.
55. Zhu X.F., Liu Z.C., Xie B.F., Li Z.M., Feng G.K., Yang D., Zeng Y.X. EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Letters 2001, 169:27-32.
56. Zou Y., Ding L., Coleman M., Wang Z. Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Letters 2009, 583:1368-1374.